PROS1 and central nervous system cancer: Finally, according to GDSC and CTRP databases, high PROS1 expression could reduce the drug sensitivity of small molecules, including AICAR, AT-7519, selumetinib, trametinib, SB590885, etc. Taken together, PROS1 is an independent risk factor for poor prognosis of glioma, which could shape the immune-suppressive tumor microenvironment to regulate the malignant progress of glioma, and may become a potential anti -cancer treatment target for patients with glioma.